⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PYXS News
Pyxis Oncology, Inc. Common Stock
Pyxis Oncology to Participate in Upcoming Investor Conferences
globenewswire.com
PYXS
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
globenewswire.com
PYXS
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
globenewswire.com
PYXS
Form 8-K
sec.gov
PYXS
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
globenewswire.com
PYXS
Pyxis Oncology Announces Proposed Public Offering
globenewswire.com
PYXS
Form 8-K
sec.gov
PYXS
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
globenewswire.com
PYXS
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
globenewswire.com
PYXS
Form 8-K
sec.gov
PYXS